Drugs / CTx1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07401121 | Jan 2026 → Dec 2027 expected | amyotrophic lateral sclerosis | Celosia Therapeutics Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTx1000 | “CTx1000 is an investigational gene therapy that encodes a degron for targeted degradation of TDP-43 following a single dose intra cisterna magna (ICM) delivery in participants...” NCT07401121 ↗ |
| Route | Other | “intra cisterna magna (ICM) delivery” NCT07401121 ↗ |